Previous 10 | Next 10 |
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development MINNEAPOLIS , Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis ...
Regulus Therapeutics (RGLS): Q3 GAAP EPS of -$0.04 beats by $0.17.Revenue of $5M beats by $4.66M.Cash and cash equivalents of $17.8MPress Release For further details see: Regulus Therapeutics EPS beats by $0.17, beats on revenue
Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD") Restructuring of Sanofi and Oxford Agreem...
Regulus Therapeutics (RGLS) soars 23% premarket after achieving the remaining $5M milestone associated with interim enrollment under its Collaboration and License Agreement with Sanofi (SNY) for its development of miR-21 programs.The milestone was triggered upon achievement of ...
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone PR Newswire LA JOLLA, Calif., Nov. 2, 2020 LA JOLLA, Calif. , Nov. 2, 2020 ...
Regulus Therapeutics (RGLS) has initiated dosing in its Phase 1b clinical study of RGLS4326 in patients with autosomal dominant polycystic kidney disease ((ADPKD)), caused by the mutations in the PKD1 or PKD2 genes, is a human monogenic disorders and a leading cause of end-stage renal disease...
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire LA JOLLA, Calif., Oct. 15, 2020 LA JOLLA, Calif. , Oct. 15, 2020 /PRN...
Are These Biotech Penny Stocks On Your Watch List Today? One of the most active industries right now is biotech & penny stocks have stood to benefit the most. Quite honestly, when you think about “novel” treatments, you’re talking about early-stage compa...
Regulus Therapeutics (RGLS) has received $5M in milestone and material payments from Sanofi. As outlined in the recent amendment to its term loan agreement with Oxford, RGLS will use the proceeds to pay down remaining principal due under the term loan to ~$9.6M.Concurrently with this recent S...
Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi Proceeds Used to Repay Debt Principal with Oxford Finance PR Newswire LA JOLLA, Calif., Oct. 13, 2020 LA JOLLA, Calif. , Oct. 13, 2020 /PRNewswire/ -- Reg...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...